Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 14/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651948 | 0.86 | HTR4 (0.78) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL1163804 | 0.86 | KDM4E (0.51) | HTR4 | |
| SCHEMBL20630963 | 0.84 | HTR4 (0.58) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL3538922 | 0.79 | HTR4 (0.47) | HTR4DRD4 | |
| SCHEMBL3942580 | 0.79 | HTR4 (0.47) | HTR4DRD4 | |
| SCHEMBL11557104 | 0.79 | HTR4 (0.72) | HTR4DRD4 | |
| SCHEMBL13880742 | 0.79 | CRBN (0.57) | HTR4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL14094313 | 0.79 | HPGD (0.55) | HTR4 | |
| SCHEMBL738237 | 0.78 | HTR4 (0.53) | HTR4 | |
| SCHEMBL20944673 | 0.78 | KMT2A (0.58) | HTR4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HTR4 3043/4885CYP1A2 56/4885CYP3A4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.